Blog
RSS FeedPosted by Michael Wonder on 07 Jun 2017
Converging on the value of value frameworks
6 June 2017 - The relentless increase in health care costs has been difficult to control and is widely believed to ...
Posted by Michael Wonder on 07 Jun 2017
Anthem to leave Ohio's Obamacare insurance market in 2018
6 June 2017 - Anthem, which has urged Republican lawmakers to commit to paying government subsidies for the Obamacare individual ...
Posted by Michael Wonder on 07 Jun 2017
FDA approves two month Aristada for treatment of schizophrenia
6 June 2017 - Approval expands Aristada's product offerings to Include once monthly, once every six weeks and once every ...
Posted by Michael Wonder on 07 Jun 2017
Pfizer receives FDA fast track designation for tafimidis for transthyretin cardiomyopathy
6 June 2017 - Tafamidis, an investigational medicine for TTR-CM a rare, progressive and fatal disease, is currently in phase ...
Posted by Michael Wonder on 06 Jun 2017
Workshop: addressing unmet needs of children with pulmonary arterial hypertension
6 June 2017 - The EMA, the United States FDA and Health Canada are co-organising a workshop to discuss the ...
Posted by Michael Wonder on 06 Jun 2017
AMA will vote on requiring drug makers to disclose prices in consumer ads
6 June 2017 - In its latest bid to restrain pharmaceutical advertising, the American Medical Association will vote on a ...
Posted by Michael Wonder on 06 Jun 2017
Senate panel to hold hearing on drug prices
6 June 2017 - The Senate's health panel will hold a hearing next week on drug pricing, questioning experts about ...
Posted by Michael Wonder on 06 Jun 2017
Drug prices become target for FDA as chief expands purview
6 June 2017 - Commissioner would prioritise additional competing generics. ...
Posted by Michael Wonder on 06 Jun 2017
Obamacare didn’t destroy insurance markets, but it also didn’t fix them
6 June 2017 - Most Americans get health insurance from a job or government program, but about 8 percent, or some ...
Posted by Michael Wonder on 06 Jun 2017
America is a world leader in health inequality
5 June 2017 - The divide between health outcomes for the richest and poorest Americans is among the largest in ...
Posted by Michael Wonder on 06 Jun 2017
BioCryst announces Rapivab paediatric sNDA acceptance
5 June 2017 - BioCryst Pharmaceuticals announced today that the U.S. FDA has accepted for review the supplemental new drug ...
Posted by Michael Wonder on 06 Jun 2017
Bristol-Myers Squibb’s Opdivo (nivolumab) + Yervoy (ipilimumab) regimen receives expanded FDA approval in unresectable or metastatic melanoma across BRAF status
23 January 2016 - Opdivo + Yervoy regimen now indicated for unresectable or metastatic melanoma patients, regardless of BRAF mutational status, ...
Posted by Michael Wonder on 06 Jun 2017
Bristol-Myers Squibb’s Opdivo (nivolumab) is the first immuno-oncology treatment to receive FDA approval based on overall survival in head and neck cancer
10 November 2016 - Opdivo is the first and only immuno-oncology treatment proven in a Phase 3 trial to significantly extend ...
Posted by Michael Wonder on 06 Jun 2017
Bayer receives FDA approval of myBETAapp and BETACONNECT Navigator
30 May 2017 - Now-approved combination of medicine, device, mobile and cloud-based health technology. ...
Posted by Michael Wonder on 05 Jun 2017
Genmab announces U.S. FDA approval of Arzerra (ofatumumab) as extended treatment for recurrent or progressive CLL
19 January 2016 - Arzerra previously approved to treat previously untreated and refractory chronic lymphocytic leukaemia indications in the US. ...